Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1898 Target Snapshot

5-hydroxytryptamine receptor 1B · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,294Compounds
558Assays
32Approved Drugs
1,821.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

5-hydroxytryptamine receptor 1B shows approved-linked disease relevance led by migraine disorder. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P28222. Start with migraine disorder, then reuse UniProt P28222 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with migraine disorder, then reuse UniProt P28222 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 8 linked drugs
Open source guide
Disease program
migraine disorder

5-hydroxytryptamine receptor 1B shows approved-linked disease relevance led by migraine disorder. 5 more disease programs remain visible in the same review block. 8 linked drugs remain visible in the same block.

Start review with migraine disorder because it currently carries approved-linked support. Linked drugs include ALMOTRIPTAN MALATE, ELETRIPTAN HYDROBROMIDE, FROVATRIPTAN SUCCINATE, NARATRIPTAN HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 8 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 1B as ChEMBL target CHEMBL1898, mapped to UniProt P28222. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5-hydroxytryptamine receptor 1B
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1898
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P28222
5-hydroxytryptamine receptor 1B
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 5-hydroxytryptamine receptor 1B is the right protein anchor across sources, using UniProt P28222 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why migraine disorder is currently framed as approved-linked support. It currently carries 8 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name5-hydroxytryptamine receptor 1B
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP28222
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label5-hydroxytryptamine receptor 1B
UniProt AccessionP28222
Component TypeProtein
Sequence Length390 aa

5-hydroxytryptamine receptor 1B

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as 5-hydroxytryptamine receptor 1B, mapped to UniProt P28222. Sequence length is 390 aa.

Mapped IDP28222
Review name5-hydroxytryptamine receptor 1B
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

5-hydroxytryptamine receptor 1B shows approved-linked disease relevance led by migraine disorder. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
migraine disorder
8 linked drugs · 8 direct · 8 efficacy
Linked drugALMOTRIPTAN MALATE
Linked drugELETRIPTAN HYDROBROMIDE
Linked drugFROVATRIPTAN SUCCINATE
Linked drugNARATRIPTAN HYDROCHLORIDE
Approved-linked Approved
cardiovascular disease
1 linked drug · 1 direct · 1 efficacy
Linked drugERGOLOID MESYLATES
Late clinical Phase III
migraine with aura
3 linked drugs · 3 direct · 3 efficacy
Linked drugRIZATRIPTAN BENZOATE
Linked drugSUMATRIPTAN
Linked drugSUMATRIPTAN SUCCINATE
Late clinical Phase III
migraine without aura
3 linked drugs · 3 direct · 3 efficacy
Linked drugRIZATRIPTAN BENZOATE
Linked drugSUMATRIPTAN
Linked drugSUMATRIPTAN SUCCINATE
Late clinical Phase III
Headache
1 linked drug · 1 direct · 1 efficacy
Linked drugNARATRIPTAN HYDROCHLORIDE
Clinical signal Phase II
depressive disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugGSK163090
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with migraine disorder because it currently carries approved-linked support. Linked drugs include ALMOTRIPTAN MALATE, ELETRIPTAN HYDROBROMIDE, FROVATRIPTAN SUCCINATE, NARATRIPTAN HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasemigraine disorder
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

32
Approved
6
Phase III
9
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC50383.0
KI1,328.0
EC50102.0
KD8.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL144397 10.05 EC50 0.09 Preclinical
CHEMBL342323 10.0 EC50 0.1 Preclinical
CHEMBL374973 10.0 Ki 0.1 Preclinical
CHEMBL438619 10.0 Ki 0.1 Preclinical
CHEMBL144030 10.0 Ki 0.1 Preclinical
CHEMBL147851 9.96 Ki 0.11 Preclinical
CHEMBL357478 9.85 Ki 0.14 Preclinical
CHEMBL339308 9.85 Ki 0.14 Preclinical
CHEMBL15928 9.85 Ki 0.14 Preclinical
CHEMBL147901 9.8 Ki 0.16 Preclinical
Distribution

pChEMBL Value Distribution

73
5.0
135
5.5
175
6.0
230
6.5
198
7.0
191
7.5
132
8.0
132
8.5
88
9.0
28
9.5
pChEMBL
Approved Drugs

Approved Drugs

CARIPRAZINE HYDROCHLORIDE
CHEMBL2024517
Approved 2015
Properties Compare Identifier
BREXPIPRAZOLE
CHEMBL2105760
Approved 2015
Properties Compare Identifier
SILODOSIN
CHEMBL24778
Approved 2008
Properties Compare Identifier
PALIPERIDONE
CHEMBL1621
Approved 2006
Properties Compare Identifier
ARIPIPRAZOLE
CHEMBL1112
Approved 2002
Properties Compare Identifier
ELETRIPTAN
CHEMBL1510
Approved 2002
Properties Compare Identifier
FROVATRIPTAN
CHEMBL1279
Approved 2001
Properties Compare Identifier
FROVATRIPTAN SUCCINATE
CHEMBL2138684
Approved 2001
Properties Compare Identifier
NARATRIPTAN
CHEMBL1278
Approved 1998
Properties Compare Identifier
RIZATRIPTAN
CHEMBL905
Approved 1998
Properties Compare Identifier
ZOLMITRIPTAN
CHEMBL1185
Approved 1997
Properties Compare Identifier
SERTINDOLE
CHEMBL12713
Approved 1996
Properties Compare Identifier
OLANZAPINE
CHEMBL715
Approved 1996
Properties Compare Identifier
NEFAZODONE HYDROCHLORIDE
CHEMBL1200492
Approved 1994
Properties Compare Identifier
RISPERIDONE
CHEMBL85
Approved 1993
Properties Compare Identifier
SUMATRIPTAN
CHEMBL128
Approved 1992
Properties Compare Identifier
CLOZAPINE
CHEMBL42
Approved 1989
Properties Compare Identifier
OXYMETAZOLINE
CHEMBL762
Approved 1986
Properties Compare Identifier
ERGOTAMINE
CHEMBL442
Approved 1948
Properties Compare Identifier
DIHYDROERGOTAMINE MESYLATE
CHEMBL1200517
Approved 1946
Properties Compare Identifier
Assay Landscape

Assay Landscape

558
Total Assays
1,040
Tested Compounds
3
Assay Types
Binding — 466 assays, 1,040 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 350 404 7.1
cell-based format 102 596 7.2
tissue-based format 8 2 8.2
assay format 4 38 6.7
cell membrane format 1 0 —
organism-based format 1 0 —
Functional — 90 assays, 184 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 42 57 6.9
cell-based format 40 120 8.2
tissue-based format 4 3 6.2
organism-based format 2 0 —
single protein format 2 4 7.7
ADME — 2 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 1 5.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine